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 Abstract: 
Introduction. Remote ischaemic preconditioning (RIPC; repeated short reversible periods of 
ischaemia) protects the heart against subsequent ischaemic injury.  We explored whether 
RIPC can attenuate post-exercise changes in cardiac troponin T (cTnT) and cardiac function 
in healthy individuals.  
Methods. In a randomised, crossover design, fourteen participants completed 1-hr cycling 
time-trials (TT) on two separate visits; preceded by RIPC (arms/legs, 4x5-min 220mmHg), or 
SHAM-RIPC (20mmHg). Venous blood was sampled before and 0, 1 and 3-h post-exercise 
to assess high sensitivity (hs-)cTnT and brain natriuretic peptide (NT-proBNP). 
Echocardiograms were performed at the same time points to assess left and right ventricular 
systolic (ejection fraction; EF & right ventricular fractional area change; RVFAC, 
respectively) and diastolic (early transmitral flow velocities; E) function. 
Results. Baseline hs-cTnT was not different between RIPC and SHAM. Post exercise hs-
cTnT levels were consistently lower following RIPC (18±3 vs 21±3; 19±3 vs 23±3; & 20±2 
vs 25±2 ng/L at 0, 1 and 3-h post-exercise, respectively; P<0.05). There was no main effect 
of time, trial or interaction for NT-proBNP and left or right ventricular EF (all P<0.05). A 
main effect of time was evident for E which transiently declined immediately after exercise to 
a similar level in both trials (0.85±0.04 vs 0.74±0.04 m.s-1, respectively; P<0.05). 
Conclusion. RIPC was associated with lower hs-cTnT levels after exercise but there was no 
independent effect of RIPC for NT-proBNP or LV systolic and diastolic function. The lower 
hs-cTnT levels after RIPC suggests that further research should evaluate the role of ischaemia 
in exercise-induced elevation in hs-cTnT.  
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Introduction: 
Several previous studies have demonstrated the presence of elevated serum levels of cardiac 
troponin (cTn), a biomarker of cardiomyocyte damage, during and after an exercise bout 
(Shave et al., 2010). Furthermore, strenuous exercise can lead to an acute, transient decrease 
in both systolic and diastolic cardiac function (Oxborough et al., 2011; Scott et al., 2009). 
Whilst studies reporting cTn-elevation or a decline in cardiac function have typically 
employed prolonged, strenuous exercise (e.g. marathon, triathlon) (Douglas et al., 1990; 
Neilan et al., 2006), comparable findings have been reported after short duration exercise (~1 
h) (Duttaroy et al., 2012; Tjora et al., 2011).  It has been speculated, but never tested, that 
acute changes in cTn and cardiac function after exercise may be related to the presence of 
local, sub-clinical ischaemia during strenuous exercise (Ellison et al., 2012). Alternative 
(non-ischaemia) explanations must also be considered to explain post-exercise elevations in 
cTn, such as mechanical stress, the atherosclerotic burden and/or the presence of myocardial 
fibrosis (Möhlenkamp et al., 2008; Breuckmann et al., 2009; Möhlenkamp et al., 2014). 
 
Ischaemic preconditioning (IPC) refers to the exposure of an organ (e.g. the heart) to repeated 
short bouts of ischaemia and was introduced in 1986 as an effective intervention to attenuate 
cardiac damage after subsequent prolonged ischaemia in animals (Murry et al., 1986). 
Interestingly, the protective effects of IPC on the heart are also present when IPC is applied 
to remote areas, such as the limbs, and is commonly referred to as remote IPC (RIPC). 
Studies in humans have demonstrated that RIPC reduces cardiac damage in response to acute 
ischaemic events and cardiac surgery (Cheung et al., 2006; Hausenloy et al., 2007; Hong et 
al., 2012; Loukogeorgakis et al., 2007; Heusch et al., 2015), although conflicting results have 
been published  (Hausenloy et al., 2015; Meybohm et al., 2015).  RIPC, therefore, provides a 
method capable of attenuating ischaemia-induced damage in the myocardium. Despite this a 
single previous study from El Messaoudi et al. found that RIPC did not alter exercise-induced 
cardiac troponin 1 (cTnI) in healthy volunteers (El Massaoudi et al., 2013). Important 
limitations in that study were the relatively mild exercise stimulus and RIPC exposure as well 
as a lack of insight into cardiac function. 
 
Consequently, the present study extended previous work and tested the hypothesis that 
exercise-related changes in cTn, NT-proBNP and cardiac function can be attenuated when 1-
h strenuous cycle exercise is preceded by RIPC and therefore may relate to ischaemia to the 
heart during strenuous exercise.  
 
Methods 
Participants 
Fourteen healthy, recreationally-trained to well-trained cyclists (Age 29 ± 8; Body Mass 71.6 
± 11.5 kg; Height 179 ± 9 cm; BMI 22.4 ± 1.6) were recruited. Participants were undertaking 
regular endurance training (>3 aerobic exercise sessions per week). We excluded subjects 
with any illness or injury that had the potential to impact the 1-hour cycling time trial (TT) 
performance. Participants who had any personal or early family history of cardiovascular 
disease were excluded from participating in the study. This study was approved by the local 
Ethics Committee and all participants provided informed consent after reading participant 
information sheets and were fully familiarized to all testing procedures. 
 
Experimental design 
In a single blind, randomised crossover-design study, participants undertook three exercise 
sessions within the physiology laboratories at Liverpool John Moores University involving a 
maximal cycling test and two time trials (TT). On the first laboratory visit, a maximal 
incremental cycling test to volitional exhaustion was completed in order to assess peak 
oxygen uptake and classify participant training status. The graded cycling test was completed 
at least 7 days before the first experimental TT. Visits 2 & 3 involved the completion a 1 hour 
cycling TT (maximum distance achieved in 1 hour) protocol preceded by RIPC or SHAM. 
TTs were separated by a minimum of 7 days. Data collection of blood samples and 
echocardiography was performed before and after (0, 1 and 3 h) the TT. All tests were 
completed at the same time of day to minimize the impact of circadian variation on exercise 
performance and outcome parameters (Atkinson and Reilly, 1996).  Participants were asked 
to attend the lab in a euhydrated state and to have abstained from intense exercise, caffeine 
and alcohol intake for a minimum of 24-hr before the exercise. 
 
Experimental protocols 
Visit 1 (maximal cycle test).  
The graded maximal cycle test was completed on a cycle ergometer (Lode, Excalibur sport 
VS, The Netherlands). The exercise test was preceded by a warm-up of 5 min at 50 W. The 
incremental test began at a workload of 50 W and increased by 25 W per min until volitional 
exhaustion was achieved.  Oxygen consumption was continually assessed using an automated 
online gas analysis system (Oxycon, COSMED, Italy). Heart rate was measured continuously 
using short-range telemetry (Polar Electro Oy, Finland). Achievement of VO2max was deemed 
when 2 of the 3 following criteria was met: 1). A plateau in VO2 despite a continual increase 
in cycling power output. 2). A heart rate (HR) 10 beats of age predicted maximum. 3). A 
respiratory exchange ratio of above 1.10 (Howley et al., 1995) 
 
Remote ischaemic preconditioning (RIPC) and SHAM.  
Before TT commencement, RIPC or SHAM was performed in the supine position using 
bilateral arterial occlusion on both the arms and legs (alternating between left and right). 
Automated pressure cuffs (Hokanson, Washington, USA) were placed proximally around the 
(left or right) upper arms and thighs. Pressure cuffs were unilaterally inflated to 220 mmHg 
(RIPC or 20 mmHg (SHAM) on ipsilateral upper and lower limbs. Limb occlusion lasted for 
5 minutes to block arterial inflow and was interspersed with 5 minutes of reperfusion. As the 
pressure cuffs were deflated, the blood pressure cuffs on the opposite side of the body and 
were inflated on both limbs for 5 minutes. This process was repeated 4 times (40 minutes 
total IPC time). 
 
Visits 2&3 Exercise Protocol:  
Immediately after the RIPC or SHAM procedure, participants completed a maximal 1-hr 
cycling TT using a computerised cycling program (Racer Mate CompuTrainer, UK). 
Participants used their own bikes where possible to improve consistency between both road- 
and lab-cycling positions during experimental trials. Rate of perceived exertion (RPE) was 
monitored every 10 minutes using the Borg scale (Borg, 1982). Heart rate (HR) was 
measured throughout exercise using short-range telemetry and average power output (W) was 
recorded from the CompuTrainer software. Participants were made aware of time and HR 
throughout the TT, but were blinded to all other physiological feedback until the completion 
of the final TT. Pre- and immediately post-exercise, body mass was recorded using an 
electronic weighing scale (SECA, Germany) along with heart rate, systolic and diastolic 
blood pressure using an automated sphygmomanometer (Dinamap, GE Medical, Wisconsin, 
USA). Biomarkers and cardiac function were assessed over four time points: Pre- (PRE); 
immediately post (POST-OH); 1-hr post (POST-1H) and 3-hr post (POST-3H) TT exercise.  
 
Measurements 
Biomarkers.  
Serum cardiac troponin T (cTnT) and NT-proBNP were assessed from whole blood sampled 
by repetitive venipuncture. In total, 4 blood samples of 5 mL were taken per trial.  Whole 
blood was spun down, pipetted and serum was stored at -80°C.  All serum samples were 
analysed in a single session.  
 
Cardiac Troponin  
The Roche diagnostics high sensitivity cardiac troponin T (hs-cTnT) assay was used. The hs-
cTnT measurements were performed using an Elecsys Cobas E-unit (Roche diagnostics, 
Haywards Heath, UK). The detection limit of the assay is 3ng/L with an upper limit of 
10000ng/L. The claimed 10% coefficient of variation (CV) is 13ng/L with a 99th centile of 
14ng/L of a healthy reference population.  
 
N terminal pro B-type natriuretic peptide. 
NT-proBNP was measured by a solid phase two site chemiluminescent sandwich 
immunoassay using an Immulite 2500 (Siemens Healthcare Diagnostics, Frimley, UK). The 
detection limit of the assay was 20ng/L with a measuring range up to 35000ng/L. The 
interassay % CV was 5.0 to 4.0% in the range 40.9 to 32096ng/L.   
 
Cardiac function.  
Cardiac function was examined using trans-thoracic echocardiography. Scans were 
performed by a trained sonographer using standardised protocols (American Society of 
Echocardiography [ASE]) (Mor-Avi et al., 2011).  All images were collected with the 
participant lying in the left lateral decubitus position. Acquisition and analysis were 
performed using VividQ and EchoPac (GE Medical, Norway). During scans all settings were 
optimized to obtain maximum signal-to-noise ratio.  Key images and outcome measures were 
as follows.  From a parasternal long axis view, M-mode scans characterized left ventricle 
(LV) dimension at end-diastole (LVED) and at end-systole (LVES).  Apical 2- and 4-
chamber views allowed the examination of LV end-diastolic (LVEDV) and end-systolic 
(LVESV) volumes using the Simpson Biplane method.  This facilitated the estimation of 
ejection fraction (EF). Right ventricular (RV) size and dimension were measured at end 
diastole from the outflow tract using a parasternal long-axis view and at the inflow from an 
apical four-chamber orientation. RV end-diastolic area and end-systolic area were calculated 
by tracing around the endocardium from a modified apical four-chamber orientation and RV 
fractional area change (RVFAC) was calculated.  LV diastolic filling was assessed using 
pulsed-wave Doppler echocardiographic recordings from the apical 4-chamber view. 
Specifically, spectral Doppler envelopes characterized from a 4 mm sample volume allowed 
measurement of peak flow velocity of the early rapid filling wave (E-wave) and peak flow 
velocity of the late filling wave due to atrial contraction (A-wave). The ratio E/A was 
calculated. In the same apical view, and using a 2 mm sample volume, tissue Doppler 
assessment of basal septal, LV  lateral wall as well as RV lateral wall peak early diastolic (E’) 
and late atrial (A’) myocardial velocities were completed.  From apical 4 chamber images we 
completed post-hoc analysis of longitudinal cardiac deformation analysis in the RV and LV. 
Myocardial speckle tracking analysis of regional strain (Ɛ) and strain rates (SR: systole, early 
diastole and atrial diastole) were determined in basal, mid and apical wall segments for the 
septum, LV lateral wall and RV lateral wall. In all cases semi-automated wall tracking was 
applied with frame rates as high as possible (but below 90 fps) and all images were optimized 
with gain, compression, and dynamic range to enhance myocardial definition.  
 
Statistics 
Statistical analysis was performed using SPSS 21.0 (SPSS, Chicago, Illinois) software.  All 
data was reported as mean ± SD and statistical significance was assumed at P ≤ 0.05. Two 
way repeated measures ANOVA (time [4 levels] - pre vs. 0 vs. 1 vs. 3 hr post-exercise, 
intervention [2 levels] - RIPC vs. control) was used to assess changes across the TT in our 
primary and secondary outcome parameters, and whether these changes differ when exercise 
was precede by RIPC. When a significant main or interaction-effect was observed, post-hoc 
analysis using Bonferroni testing to correct for multiple comparisons was performed. 
 
Results: 
Maximal cycling test: The mean VO2peak was 50.1 ± 7.6 mL.kg.min
-1. Peak HR was 182 ± 9 
beats.min-1 and the average peak power attained was 346 ± 63 W. All individuals reported 
that lower limb local fatigue was responsible for cessation of exercise. 
 
1-hr time trial performance: Both average power output and cycle distance were not different 
between RIPC and SHAM groups (W: 179 ± 47 vs. 183 ± 53, P > 0.05; & Distance: 31.96 ± 
3.08 km vs. 32.10 ± 2.47 km, P > 0.05, respectively). No significant changes in body mass or 
blood pressure were found between or within trials (P > 0.05, respectively). Average HR was 
not different between RIPC and SHAM (154 ± 16 beats.min-1 vs. 151 ± 16 beats.min-1, P > 
0.05).  Similarly, there was no difference in average RPE between both RIPC and SHAM 
conditions (15 ± 2 vs. 15 ± 1, respectively, P > 0.05). 
 
Cardiac biomarkers: At rest, hs-cTnT was not different between RIPC and SHAM trials (P > 
0.05). Absolute hs-cTnT levels were lower after RIPC than SHAM across all time points 
post-exercise (main effect for trial: P < 0.05), but there was no main effect of time or time-
by-trial interaction (both P > 0.05, Figure 1a). Maximal values for hs-cTnT occurred POST-
3H (RIPC: 20 ± 9 ng/L vs. SHAM: 25 ± 8 ng/L, P = 0.08). No main effect of time, trial or 
time-by-trial interaction was observed for NT-proBNP (all P > 0.05, Figure 1b). 
 Cardiac function: There was an effect of time for HR after exercise (P < 0.001) but no time-
by-trial interaction (Table 1). There was no main effect of time, trial or time-by-trial 
interaction for LVEDV, a surrogate of preload, LVEF or RVFAC (P > 0.05, Table 1). A main 
effect of time was evident for E peak velocity (P < 0.05) with E dropping immediately after 
exercise in both trials with a recovery by POST-3H. Changes in E contributed to a drop in 
E/A immediately post-exercise, but this did not reach statistical significance (P = 0.06). 
Additionally, there was no change in E/e’ ratio between conditions (P > 0.05). A main effect 
of time was also noted for E’ in the LV (Table 2), although these changes were small and did 
not differ between SHAM and RIPC trials. A main effect of time was also observed for LV 
longitudinal peak SSR with values increasing at POST-1H and POST-3H (P = 0.003 and 
0.007, respectively, Table 2). A main effect of time was noted for LV longitudinal ASR with 
increased values at POST-3H (P = 0.006) as well as a main effect of trial with lower values 
reported throughout the RIPC trial (P = 0.011). No effect of time or trial was observed for 
peak Ɛ, ESR or SSR (P > 0.05). 
 
Discussion 
The primary aim of this study was to investigate whether RIPC influenced exercise-induced 
changes in cardiac biomarker release and cardiac function. The key findings from the current 
study are; (1) there is some evidence that hs-cTnT release following 1-hour TT cycling is 
attenuated when exercise is preceded by RIPC, (2) post-exercise NT-proBNP were not 
altered by RIPC, and (3) RIPC prior to a 1-hour cycling time trial did not influence post-
exercise cardiac function. The association of lower hs-cTnT levels after RIPC suggests that 
ischaemia may contribute (in part) to exercise-induced elevation in hs-cTnT. 
 
Cardiac Biomarkers 
Baseline hs-cTnT was found to be slightly higher (> 14 ng/L) in the current study. A previous 
large sample study (n = 545) reported a 99th percentile of 30 ng/L (Collinson et al., 2012) 
which suggests the current data are likely within the ‘normal’ spectrum. A post-exercise 
elevation in hs-cTnT, a highly specific marker of cardiomyocyte insult, has been observed 
previously (Duttaroy et al., 2012; La Gerche et al., 2008). The increase in hs-cTnT values 
post-exercise in the current study was smaller than those observed in past research (Duttaroy 
et al., 2012), which may be partially explained by between-study differences in exercise 
intensity and/or exercise duration (Fu et al., 2009) or the higher  baseline levels observed 
compared to previous work.  
 
A systematically lower set of hs-cTnT data was observed after exercise in the RIPC 
compared to the SHAM trial (significant main effect of trial). This provides the first, 
tentative, suggestion that RIPC can attenuate hs-cTnT release that occurs as a consequence of 
acute endurance exercise. This contradicts the only previous study that examined the effects 
of RIPC on exercise-related changes in cTnI, which did not find an effect of RIPC (El 
Messaoudi et al., 2013). The difference in outcomes may be explained by a combination of 
factors, related to the exercise- and RIPC-stimulus, but also variability in participant training 
status.  El Massaoudi et al. (2013) included relatively untrained subjects, whilst the intensity 
of exercise was lower than in the present study. Furthermore, El Messaoudi et al. employed a 
3x5 minute bilateral forearm RIPC protocol occluding a smaller muscle mass for a shorter 
duration compared to the current study, which may have limited the cardio-protective 
stimulus.  
 
It is tempting to suggest that the mechanism(s) underpinning the lower hs-cTnT data after 
exercise in the RIPC trial are consistent with the ischaemia-reperfusion induced cardio-
protective adaptation observed in previous animal studies using IPC (Jean-St-Michel et al., 
2011). While direct evidence between RIPC and inhibition of mitochondrial permeability 
transition pore (mPTP) opening is yet to be established (Sharma et al., 2015), it is apparent 
that mitochondrial KATP channel opening does occur. RIPC inhibits mPTP opening upon 
reperfusion and offers cardio-protection in similar fashion to both the reperfusion injury 
salvage kinase (RISK) and survivor activating factor enhancement (SAFE) pathways, which 
are also activated following RIPC (Heusch et al., 2015; Sharma et al., 2015). Opening of 
KATP channels additionally activates downstream signalling of protein kinase C-ε, shown to 
also offer cardio-protective effects (Wolfrum et al., 2002). It is suggested both humoral and 
neural pathways could be responsible for the transmission of cardio-protective signals to the 
heart following RIPC (Sharma et al., 2015), however the exact contribution of each pathway 
remains unclear. Therefore any resultant change from RIPC does not necessarily provide 
direct evidence for an ischaemic mediated mechanism or event.  
 
Sphingosine-1-phosphate (S1P) is a molecule recently demonstrated to reduce 
ischaemia/reperfusion (I/R) induced cardiac damage (Santos-Gallego et al., 2016) and to 
mediate the mechanism of RIPC-induced cardio-protection (Jin et al., 2004). Interestingly, 
S1P can also be produced in skeletal muscle (Baranowski et al., 2015), thus intramuscular 
S1P release in response to RIPC could influence the cardio-protective response following 
exercise. Additionally, the observation that plasma S1P levels are only elevated by high-
intensity exercise (Baranowski et al., 2015) could explain why in previous work (Neilan et 
al., 2006), athletes with less training experience (i.e. less S1P release) showed more severe 
exercise-induced cardiac damage. 
 Whilst our study may provide the first indirect evidence of the role of ischaemia in exercise-
induced hs-cTnT elevation, there are some important caveats.  Firstly, the elevation in hs-
cTnT after exercise in the SHAM trial was small compared to previous studies in different 
exercise circumstances (Shave et al., 2010). Secondly there was no significant statistical 
interaction term (time by trial) for the hs-cTnT data. Finally, there was no other corroborative 
evidence of ischaemia, such as ECG changes.  At this preliminary stage in the evaluation of 
mechanism(s) underpinning hs-cTnT changes after acute exercise (and the ability of RIPC to 
prevent such changes) we cannot, categorically, rule out other potential mechanisms. 
 
We did not observe any effect of time, trial or an interaction of these factors on NT-proBNP. 
An elevation in NT-proBNP has been positively correlated with exercise duration, with 
significantly higher serum levels occurring post-ultramarathon (100km run) when compared 
to marathon running (Scharhag et al., 2005). The time (or exercise volume) dependent 
increase in NT-proBNP reflects an increased BNP expression in over-stretched myocytes in 
vitro. On the basis that no changes in NT-proBNP were reported after both short-endurance 
and high-intensity exercise (Benda et al., 2015; El Massaoudi et al., 2013), it is suggested the 
exercise volume in the current study may have been insufficient to stimulate a significant NT-
proBNP response. 
 
Cardiac Function 
No post-exercise changes in LV systolic function were observed in either trial. This is in line 
with previous studies employing a relatively short (1 hr) endurance exercise exposure 
(Oxborough et al., 2012). For example, Palatini et al. reported no change in LV systolic 
function following 50-80 minutes of cycling to exhaustion at anaerobic threshold (Palatini et 
al., 1994). It would seem that systolic function is well maintained in the face of this type of 
acute exercise exposure. Nonetheless, small changes in diastolic function were observed 
during recovery from exercise in both trials in our study, and as such, changes were not 
mediated by RIPC.  A transient decline in peak E diastolic flow velocity after exercise, with a 
return to baseline by the POST-3H, has been confirmed in a range of previous studies and 
this effect is summarised in a meta-analysis (Middleton et al., 2006). There is evidence to 
suggest transient declines in diastolic, but not systolic function can occur following shorter 
duration exercise (<6 hours) (Middleton et al., 2006). A post-exercise, transient decline in 
diastolic function has been postulated to be due to a decrease in preload, ischaemia and 
damage, and/or other intrinsic processes (Oxborough et al., 2010).  The current study would 
tend to suggest that ischaemia is not a key candidate, due to the consistency of post-exercise 
changes in these measures of diastolic function in both the RIPC and SHAM trials. Further 
research is needed, preferably in situations where the heart is exposed to a longer period of 
exercise. 
 
Implications 
Based on our observations and the post-exercise kinetics of cTnT release observed in other 
work (Middleton et al., 2008), it is likely the small post-exercise changes in hs-cTnT do not 
represent long term irreversible myocardial damage (La Gerche et al., 2008; Shave et al., 
2010). The observation that RIPC may at least partially mediate changes in hs-cTnT 
appearance after prolonged exercise warrants on-going study. It is also apparent that post-
exercise changes in LV diastolic function are small, transient and likely to have no 
performance and/or clinical relevance (Middleton et al., 2006). In the current study, there was 
no association between hs-cTnT and changes in LV diastolic function. The lack of 
association between changes in cTn and cardiac function after endurance exercise is common 
(Shave et al., 2010) and supports the hypothesis that increases in cTn and decreases in LV 
function represent two different phenomenon that are not causally linked. 
 
Limitations 
Individual variability in hs-cTnT response in the current study likely restricted statistical 
significance on post-hoc analysis. The relatively small sample size used (N=14) may have 
also contributed to absence of statistical significance for the post-hoc comparisons. The 
limited exercise volume and blood sampling protocol employed in the current study may 
have led to “blunted” hs-cTnT data. Whilst there is little data assessing cTn kinetics during 
and after endurance cycling, Middleton et al. (2008) noted that cTnT peaked between 60-120 
min during treadmill running with a secondary peak between 3-12 hours post exercise. A 
more frequent blood sampling protocol (between 3 & 12 hours post-exercise) may have 
further clarified any between-trial differences observed in cTnT based on the trend for 
increasing post-exercise hs-cTnT levels in SHAM at POST-3H, and subsequently, a 
progressive increase in the difference between SHAM vs RIPC. It is therefore advisable that 
future RIPC studies should employ more frequent blood draws and employ a larger exercise 
stimulus. The use of a 7 day washout between trials ensured participants were in similar 
physical condition. A longer washout period may be advisable in future studies following 
new observations of circulating cardio-protective factors 6 days after RIPC treatment in 
animals (Hildebrandt et al., 2016). The use of counterbalanced and randomized trial order in 
the present study should have accounted for any delayed humoral alterations during SHAM 
condition exercise. All participants were instructed to undertake no exercise 24 hours prior to 
laboratory visits but we cannot confirm if any (intense) exercise performed 24-48 hour prior 
to laboratory testing, influenced baseline hs-cTnT data. 
 
Conclusion 
Overall, serum hs-cTnT concentrations were lower in the RIPC vs SHAM condition.  Whilst 
there was a trend for an increasing difference in hs-cTnT between conditions as time 
progressed, this was not met with a significant main effect for time, or time by trial 
interaction. This provides the first, indirect, evidence that ischaemia may be implicated as a 
mechanism in changes in hs-cTnT post-exercise. RIPC did not mediate post-exercise changes 
in NT-proBNP, LV systolic function or LV diastolic function, providing further support to 
the hypothesis that exercise-induced changes in cTn may not be directly related to changes in 
cardiac function. 
 
NEW FINDINGS / BRIEF PERSPECTIVE: 
 
RIPC is associated with reduced myocardial infarct following ischaemic exposures. The effect RIPC 
can have on both cTnT response and cardiac function following an intense exercise TT bout has not 
previously been explored. 
 
We show that RIPC is associated with lower cTnT elevation following cycling TT exercise, providing 
the first, indirect evidence that ischaemia may be implicated as a mechanism in changes in cTnT post-
exercise. 
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Figures Legend: 
 
Figure 1: hs-cTnT  (A) and NT-proBNP (B) release at pre, POST-0H, POST-1H, & POST-
3H exercise time points during both IPC (open squares) and SHAM (solid circles) conditions 
in healthy volunteers (n = 14). Error bars represent SD. 
  
Table 1: Cardiac loading and rate changes, POST-0H, POST-1H, & POST-3H exercise time points during 
both RIPC and SHAM conditions in healthy volunteers (n = 14) 
* Significantly different between IPC and SHAM conditions 
 
Abbreviations: HR, Heart Rate; LVEDV, Left Ventricular End Diastolic Volume; SBP, Systolic Blood Pressure; 
DBP, Diastolic Blood Pressure 
 
  
 
Intervention       
 Pre POST-0H POST-1H POST-3H   P values 
HR (beats.min-1)               
RIPC 55 ± 9 72 ± 12 64 ± 13.3 65  ± 10   Condition 0.40 
SHAM 56 ± 8 70 ± 14 70 ± 13 63  ± 13   time < 0.001 
            Con*time 0.60 
                
LVEDV (ml)               
RIPC 126 ± 22 123 ± 21 127 ± 24 129  ± 24   Condition 0.42 
SHAM 130 ± 25 124 ± 21 124 ± 27 124 ± 26   time 0.30 
            Con*time 0.37 
                
SBP (mmHg)               
RIPC 119 ± 9 122 ± 18 118 ± 9 119 ± 7   Condition 0.24 
SHAM 122 ± 12 119 ± 11 119 ± 11 125 ± 10   time 0.74 
            Con*time 0.59 
                
DBP (mmHg)               
RIPC 63 ± 6 64 ± 13 61 ± 5 62 ± 6   Condition 0.28 
SHAM 66 ± 11 64 ± 10 63 ± 8 65 ± 9   time 0.76 
            Con*time 0.92 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Measures of left ventricular functional response at pre, POST-0H, POST-1H, & POST-3H exercise 
time points during both RIPC and SHAM conditions in healthy volunteers (n = 14). 
 
  Intervention       
  Pre POST-0H POST-1H POST-3H   P values 
LV EF (%)               
RIPC 53 ± 7 53 ± 6 54 ± 5 56  ± 4   Condition 0.26 
SHAM 55 ± 5 54 ± 6 55 ± 6 54 ± 6   time 0.50 
            Con*time 0.44 
LV S' (m.s-1)               
RIPC 0.11 ± 0.02 0.11 ± 0.02 0.12 ± 0.03 0.12 ± 0.02   Condition 0.93 
SHAM 0.11 ± 0.02 0.12 ± 0.03 0.11 ± 0.03 0.12 ± 0.02   time < 0.001 
            Con*time 0.62 
LV SSR (.s-1)               
RIPC (-)1.1 ± 0.2 (-)1.1  ± 0.1 (-)1.3 ± 0.2 (-)1.2 ± 0.1   Condition 0.24 
SHAM (-)1.2 ± 0.2 (-)1.2  ± 0.2 (-)1.3 ± 0.2 (-)1.5 ± 0.3   time 0.001 
            Con*time 0.90 
LV E (m.s-1)               
RIPC 0.86 ± 0.14 0.75  ± 0.16 0.77  ± 0.16 0.84  ± 0.18   Condition 0.83 
SHAM 0.81  ± 0.15 0.73  ± 0.14 0.81  ± 0.13 0.86  ± 0.17   time 0.035 
            Con*time 0.71 
LV A (m.s-1)               
RIPC 0.44  ± 0.12 0.49  ± 0.14 0.45  ± 0.12 0.50  ± 0.12   Condition 0.75 
SHAM 0.46  ± 0.11 0.47  ± 0.15 0.50  ± 0.1 0.49  ± 0.13   time 0.58 
            Con*time 0.80 
LV E/A               
RIPC 2.04 ± 0.46 1.59 ± 0.38 1.78 ± 0.57 1.76 ± 0.56   Condition 0.60 
SHAM 1.82 ± 0.4 1.64 ± 0.44 1.7 ± 0.53 1.82 ± 0.46   time 0.06 
            Con*time 0.60 
LV E/e'               
RIPC 4.69 ± 1.05 4.25 ± 1.16 4.26 ± 1.24 4.30 ± 1.12   Condition 0.35 
SHAM 4.34 ± 1.11 4.05 ± 1.14 4.25 ± 0.92 4.39 ± 1.07   time 0.12 
            Con*time 0.67 
LV E' (m.s-1)               
RIPC 0.19 ± 0.04 0.18 ± 0.03 0.19 ± 0.02 0.20 ± 0.03   Condition 0.69 
SHAM 0.19 ± 0.04 0.19 ± 0.03 0.19 ± 0.04 0.20 ± 0.04   time 0.018 
            Con*time 0.90 
LV A' (m.s-1)               
RIPC 0.07 ± 0.02 0.08 ± 0.02 0.09 ± 0.02 0.08 ± 0.02   Condition 0.14 
SHAM 0.07 ± 0.01 0.07 ± 0.02 0.09 ± 0.02 0.08 ± 0.02   time < 0.001 
            Con*time 0.48 
LV ESR (.s-1)               
RIPC 1.9 ± 0.3 1.9  ± 0.5 2.0 ± 0.4 1.9 ± 0.3   Condition 0.27 
SHAM 2.0 ± 0.4 1.8  ± 0.4 2.1 ± 0.5 2.3 ± 0.8   time 0.16 
            Con*time 0.20 
* Significantly different between IPC and SHAM conditions 
Abbreviations: LV, Left Ventricle; RV, Right Ventricle; EF, Ejection Fraction; S’, Systolic myocardial tissue 
velocity; SSR, Systolic strain rate; E, Early diastolic filling; A, Late diastolic filling; E/A, Early to late diastolic 
ratio; E’, Early diastolic myocardial velocity; A’, Late diastolic myocardial velocity; ESR, Early diastolic strain 
rate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 3: Measures of right ventricular response at pre, POST-0H, POST-1H, & POST-3H exercise time points 
during both RIPC and SHAM conditions in healthy volunteers (n = 14). 
 
  Intervention       
  Pre POST-0H POST-1H POST-3H   P values 
RVFAC (%)               
RIPC 43.2 ± 6.4 43.6 ± 5.2 45.5 ± 8.2 44.4 ± 4.7   Condition 0.71 
SHAM 42.6 ± 7.6 45 ± 7.6 44.1 ± 7.3 43.6 ± 6.9   time 0.49 
            Con*time 0.77 
RV S' (m.s-1)               
RIPC 0.14 ± 0.02 0.13 ± 0.02 0.15 ± 0.02 0.16 ± 0.02   Condition 0.10 
SHAM 0.13 ± 0.02 0.13 ± 0.02 0.15 ± 0.02 0.15 ± 0.03   time < 0.001 
            Con*time 0.79 
RV SSR (.s-1)               
RIPC (-)1.5 ± 0.2 (-)1.4  ± 0.3 (-)1.5 ± 0.4 (-)1.2 ± 0.2   Condition 0.27 
SHAM (-)1.4 ± 0.2 (-)1.6  ± 0.3 (-)1.5 ± 0.3 (-)1.6 ± 0.2   time 0.59 
            Con*time 0.68 
RV E' (m.s-1)               
RIPC 0.16 ± 0.02 0.16 ± 0.04 0.16 ± 0.02 0.16 ± 0.03   Condition 0.94 
SHAM 0.16 ± 0.03 0.16 ± 0.03 0.17 ± 0.02 0.16 ± 0.04   time 0.73 
            Con*time 0.93 
RV A' (m.s-1)               
RIPC 0.11 ± 0.03 0.09 ± 0.03 0.12 ± 0.03 0.13 ± 0.03   Condition 0.18 
SHAM 0.10 ± 0.04 0.09 ± 0.04 0.12 ± 0.03 0.11 ± 0.03   time < 0.001 
            Con*time 0.53 
RV ESR (.s-1)               
RIPC 2.3 ± 0.3 2.3  ± 0.7 2.1 ± 0.5 2.0 ± 0.4   Condition 0.06 
SHAM 2.0 ± 0.4 2.1  ± 0.3 1.9 ± 0.4 2.2 ± 0.4   time 0.11 
            Con*time 0.97 
* Significantly different between IPC and SHAM conditions 
 
Abbreviations: RV, Right Ventricle; RVFAC, Right ventricular fractional area change; S’, Systolic myocardial 
tissue velocity; SSR, Systolic strain rate; E, Early diastolic filling; A, Late diastolic filling; E/A, Early to late 
diastolic ratio; E’, Early diastolic myocardial velocity; A’, Late diastolic myocardial velocity; ESR, Early 
diastolic strain rate 
